PIK3CD and B-cell chronic lymphocytic leukemia: p110δ is in integral component of B cell receptor signalling in chronic lymphocytic leukaemia (CLL) and downregulation of p110δ with idelalisib in combination with rituximab demonstrated significant overall responses rates with progression free and overall survival benefit [104].